MIND TECHNOLOGY, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MIND TECHNOLOGY, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jan 31, 2020 | $13.26M | Apr 28, 2020 |
| FY2020 | Oct 31, 2019 | $10.66M | Apr 28, 2020 |
| FY2020 | Jul 31, 2019 | $8.90M | Apr 28, 2020 |
| FY2020 | Apr 30, 2019 | $9.86M | Apr 28, 2020 |
| FY2020 | Jan 31, 2019 | $12.33M | Apr 28, 2020 |
| FY2020 | Oct 31, 2018 | $14.65M | Apr 28, 2020 |
| FY2020 | Jul 31, 2018 | $8.35M | Apr 28, 2020 |
| FY2020 | Apr 30, 2018 | $7.61M | Apr 28, 2020 |
| FY2019 | Jan 31, 2018 | $10.36M | Apr 5, 2019 |
| FY2019 | Oct 31, 2017 | $8.64M | Apr 5, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $46.86M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $36.51M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $25.01M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $23.11M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $21.22M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $29.92M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $25.77M | Apr 28, 2020 |
| FY2019 | Jan 31, 2018 | $0 | Apr 5, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $20.97M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $15.97M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $9.95M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $6.02M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $7.31M | Apr 29, 2022 |
| FY2020 | Jan 31, 2020 | $5.95M | Apr 28, 2020 |
| FY2020 | Oct 31, 2019 | $4.05M | Apr 28, 2020 |
| FY2020 | Jul 31, 2019 | $2.88M | Apr 28, 2020 |
| FY2020 | Apr 30, 2019 | $3.74M | Apr 28, 2020 |
| FY2020 | Jan 31, 2019 | $3.41M | Apr 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $5.07M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $274.0K | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | ($8.83M) | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | ($15.09M) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | ($20.31M) | Apr 29, 2022 |
| FY2020 | Jan 31, 2020 | ($3.71M) | Apr 28, 2020 |
| FY2020 | Oct 31, 2019 | ($2.03M) | Apr 28, 2020 |
| FY2020 | Jul 31, 2019 | ($3.14M) | Apr 28, 2020 |
| FY2020 | Apr 30, 2019 | ($2.42M) | Apr 28, 2020 |
| FY2020 | Jan 31, 2019 | ($4.16M) | Apr 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $6.82M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $518.0K | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | ($5.65M) | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | ($14.54M) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | ($14.33M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($6.29M) | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | ($13.02M) | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | ($19.71M) | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | ($31.29M) | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | ($26.76M) | Apr 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $1.91M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $2.13M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $1.37M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $3.60M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $3.00M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $1.85M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $1.16M | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $1.50M | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $974.0K | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $931.0K | Apr 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $11.29M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $12.14M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $12.88M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $14.76M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $12.65M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $14.14M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $20.91M | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $19.66M | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $19.75M | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $18.04M | Apr 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $651.0K | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | ($4.97M) | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | ($2.91M) | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | ($17.13M) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | ($6.36M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($5.82M) | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | ($5.46M) | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $719.0K | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $3.15M | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $15.05M | Apr 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $437.0K | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $290.0K | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $570.0K | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $834.0K | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $90.0K | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $1.04M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $814.0K | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $407.0K | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $283.0K | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $336.0K | Apr 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $36.72M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $33.49M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $32.86M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $42.02M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $39.76M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $58.23M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $65.30M | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $73.68M | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $94.71M | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $134.76M | Apr 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $9.39M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $10.85M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $9.81M | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $11.76M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $9.35M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $10.58M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $8.62M | Apr 28, 2020 |
| FY2019 | Jan 31, 2018 | $7.83M | Apr 5, 2019 |
| FY2018 | Jan 31, 2017 | $13.78M | Apr 13, 2018 |
| FY2017 | Jan 31, 2016 | $29.72M | Apr 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $27.33M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $22.64M | Apr 25, 2025 |
| FY2025 | Jan 31, 2023 | $23.05M | Apr 25, 2025 |
| FY2024 | Jan 31, 2022 | $30.26M | Apr 30, 2024 |
| FY2023 | Jan 31, 2021 | $30.42M | May 1, 2023 |
| FY2022 | Jan 31, 2020 | $47.65M | Apr 29, 2022 |
| FY2021 | Jan 31, 2019 | $56.68M | Apr 16, 2021 |
| FY2020 | Jan 31, 2018 | $65.85M | Apr 28, 2020 |
| FY2020 | Jan 31, 2017 | $80.93M | Apr 28, 2020 |
| FY2019 | Jan 31, 2016 | $105.04M | Apr 5, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jan 31, 2022 | $0 | Apr 29, 2022 |
| FY2022 | Jan 31, 2021 | $0 | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $2.53M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $2.53M | Apr 28, 2020 |
| FY2020 | Jan 31, 2018 | $2.53M | Apr 28, 2020 |
| FY2019 | Jan 31, 2017 | $4.00M | Apr 5, 2019 |
| FY2018 | Jan 31, 2016 | $4.16M | Apr 13, 2018 |
| FY2017 | Jan 31, 2015 | $5.59M | Apr 7, 2017 |
| FY2016 | Jan 31, 2014 | $4.32M | Apr 7, 2016 |
| FY2015 | Jan 31, 2013 | $4.32M | Apr 8, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($108.45M) | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | ($128.31M) | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | ($127.64M) | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | ($117.86M) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | ($99.87M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($77.31M) | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | ($63.97M) | Apr 28, 2020 |
| FY2019 | Jan 31, 2018 | ($42.43M) | Apr 5, 2019 |
| FY2018 | Jan 31, 2017 | ($20.45M) | Apr 13, 2018 |
| FY2017 | Jan 31, 2016 | $13.19M | Apr 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $5.34M | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | $5.29M | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | $778.0K | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | $5.11M | May 1, 2023 |
| FY2022 | Jan 31, 2021 | $4.61M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $3.09M | Apr 16, 2021 |
| FY2020 | Jan 31, 2019 | $9.39M | Apr 28, 2020 |
| FY2019 | Jan 31, 2018 | $9.90M | Apr 5, 2019 |
| FY2018 | Jan 31, 2017 | $2.90M | Apr 13, 2018 |
| FY2017 | Jan 31, 2016 | $3.77M | Apr 7, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $0 | Apr 13, 2018 |
| FY2018 | Jan 31, 2017 | $6.37M | Apr 13, 2018 |
| FY2017 | Jan 31, 2016 | $20.48M | Apr 7, 2017 |
| FY2016 | Jan 31, 2015 | $26.36M | Apr 7, 2016 |
| FY2015 | Jan 31, 2014 | $22.20M | Apr 8, 2015 |
| FY2012 | Jan 31, 2013 | $4.24M | Apr 4, 2013 |
| FY2012 | Jan 31, 2012 | $12.78M | Apr 4, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | 4 | Apr 25, 2025 |
| FY2025 | Jan 31, 2024 | (2) | Apr 25, 2025 |
| FY2024 | Jan 31, 2023 | (8) | Apr 30, 2024 |
| FY2023 | Jan 31, 2022 | (1) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | (1) | Apr 29, 2022 |
| FY2020 | Jan 31, 2020 | 0 | Apr 28, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Jan 31, 2019 | 0 | Apr 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jan 31, 2023 | 0 | May 1, 2023 |
| FY2023 | Jan 31, 2022 | (1) | May 1, 2023 |
| FY2022 | Jan 31, 2021 | (1) | Apr 29, 2022 |
| FY2020 | Jan 31, 2020 | 0 | Apr 28, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Apr 30, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Jan 31, 2019 | 0 | Apr 28, 2020 |
| FY2020 | Oct 31, 2018 | 0 | Apr 28, 2020 |
| FY2020 | Jul 31, 2018 | 0 | Apr 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 28, 2023 | 1.41M | Apr 25, 2025 |
| FY2025 | Sep 27, 2023 | 13.79M | Apr 25, 2025 |